The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review

Indian Journal of Pharmacology

Volumn 44, Issue 6, 2012, Pages 665-671

  Chandrashekara, S ^a  

^a NHCL   (India)

Author keywords

Autoimmune disease; homeostasis; immune modulation; immunosuppressive drugs; strtegies

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL PROTOCOL; EVIDENCE BASED MEDICINE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; NEOPLASM; NONHUMAN; PRACTICE GUIDELINE; REVIEW; RHEUMATOID ARTHRITIS; TRANSPLANTATION; VIRUS INFECTION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION;

EID: 84870018849     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.103235     Document Type: Review

References (57)

1. Eaton WW, Rose NR, Kalaydjian A, Pedersen MG, Mortensen PB. Epidemiology of autoimmune diseases in Denmark. J Autoimmun 2007;29:1-9.
2. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009;33:197-207.
3. Urowitz MB, Gladman DD. How to improve morbidity and mortality in systemic lupus erythematosus. Rheumatology (Oxford) 2000;39:238-44.
4. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297.
5. Sakaguchi S. Regulatory T cells: Key controllers of immunologic self-tolerance. Cell 2000;101:455-8.
6. Adams DD, Knight JG, Ebringer A. Autoimmune diseases: Solution of the environmental, immunological and genetic components with principles for immunotherapy and transplantation. Autoimmun Rev 2010;9:525-30.
7. Doria A, Sarzi-Puttini P, Shoenfeld Y. Infections, rheumatism and autoimmunity: The conflicting relationship between humans and their environment. Autoimmun Rev 2008;8:1-4.
8. Stojanovich L. Stress and autoimmunity. Autoimmun Rev 2010;9:A271-6.
9. Christen U, von Herrath MG. Initiation of autoimmunity. Curr Opin Immunol 2004;16:759-67.
10. Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest 2007;117:871-3.
11. Topfer F, Gordon T, McCluskey J. Intra-and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sci U S A 1995;92:875-9.
12. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
13. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006;129:1953-71.
14. Singh R, Robinson DB, El-Gabalawy HS. Emerging biologic therapies in rheumatoid arthritis: Cell targets and cytokines. Curr Opin Rheumatol 2005;17:274-9.
15. Stott DI, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest 1998;102:938-46.
16. Manz RA, Moser K, Burmester GR, Radbruch A, Hiepe F. Immunological memory stabilizing autoreactivity. Curr Top Microbiol Immunol 2006;305:241-57.
17. Domínguez Rodríguez A, Abreu González P, García MJ, de la Rosa A, Vargas M, Marrero F. Circadian variations in proinflammatory cytokine concentrations in acute myocardial infarction. Rev Esp Cardiol 2003;56:555-60.
18. Gokhale R, Chandrashekara S, Vasanthakumar KC. Cytokine response to strenuous exercise in athletes and non-athletes-an adaptive response. Cytokine 2007;40:123-7.
19. Moudgil KD, Choubey D. Cytokines in autoimmunity: Role in induction, regulation, and treatment. J Interferon Cytokine Res 2011;31:695-703.
20. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995;273:808-12.
21. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007;66:1356-62.
22. Feldmann M, Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005; f435:612-9.
23. Böhm M, Luger TA, Schneider M, Schwarz T, Kuhn A. New insight into immunosuppression and treatment of autoimmune diseases. Clin Exp Rheumatol 2006;24(1 Suppl 40):S67-71.
24. Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, Borg EJ, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797-807.
25. Bisno AL, Gerber MA, Gwaltney JM Jr, Kaplan EL, Schwartz RH; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of Group A streptococcal pharyngitis. Infectious Diseases Society of America. Clin Infect Dis 2002;35:113-25.
26. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.
27. Deresinski S. Principles of antibiotic therapy in severe infections: Optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007;45 Suppl 3:S177-83.
28. Casadevall A. Crisis in infectious diseases: Time for a new paradigm? Clin Infect Dis 1996;23:790-4.
29. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [Internet]. 1-167. Available from: http://aidsinfo. nih.gov/contentfiles/AdultandAdolescentGL002534.pdf. [Last accessed on 2011 Oct. 14].
30. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009;50:661-2.
31. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
32. Simon C, Watson M, Drake A, Fenton A, McLoughlin C. Principles of cancer treatment. InnovAiT [Internet]. 1:107-18. Available from: http://rcgp-innovait. oxfordjournals.org/content/1/2/107.full.pdf+html. [Last accessed in 2008]
33. Perry MC. Principles of cancer therapy. In: Goldman L, Ausiello D, editors. Cecil Medicine. Philadelphia: Saunders Elsevier; 2007. p. 192.
34. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med 1994;121:281-8.
35. Chakrapani A, Wraith JE. Principles of management of the more common metabolic disorders. Curr Paediatrics 2002;12:117-24.
36. Cohen IR. Treatment of autoimmune disease: To activate or to deactivate? Chem Immunol 1995;60:150-60.
37. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971-82.
38. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: Present approaches and a look to the future. Neuromuscul Disord 2006;16:223-36.
39. Krupica T Jr, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: A two-hit model. Clin Immunol 2006;120:121-8.
40. Kaminitz A, Mizrahi K, Yaniv I, Stein J, Askenasy N. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun 2010;35:145-52.
41. Schuetz C, Niehues T, Friedrich W, Schwarz K. Autoimmunity, autoinflammation and lymphoma in combined immunodeficiency (CID). Autoimmun Rev 2010;9:477-82.
42. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: Pathogenesis, clinical manifestations and management. Drugs 2008;68:191-208.
43. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev 2009; CD007848.
44. Tyndall A, Gratwohl A. The use of high dose immunoablative therapy with hematopoietic stem cell support therapy in the treatment of severe autoimmune diseases. Int J Hematol 2002;76:218-22.
45. Sibilia J. Novel concepts and treatments for autoimmune disease: Ten focal points. Joint Bone Spine 2004;71:511-7.
46. Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006;117:289-300.
47. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Metaanalysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53.
48. Kennedy J, Tuleu I, Mackay K. Unfilled prescriptions of medicare beneficiaries: Prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm 2008;14:553-60.
49. Bertsias G, Ioannidis J P, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205.
50. Scherer HU, Dörner T, Burmester GR. Patient-tailored therapy in rheumatoid arthritis: An editorial review. Curr Opin Rheumatol 2010;22:237-45.
51. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 2011;70:4-7.
52. Carlson RJ. The disruptive nature of personalized medicine technologies: Implications for the health care system. Public Health Genomics 2009;12:180-4.
53. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81.
54. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29:1631-8.
55. Moore B. The relationship of dosage of a drug to the size of the animal treated, especially in regard to the cause of the failures to cure trypanosomiasis, and other protozoan diseases in man and in large animal. Biochem J 1909;4:323-30.
56. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
57. Emery P. Treatment of rheumatoid arthritis. BMJ 2006;332:152-5.